A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
This pilot Phase II study is designed to evaluate the efficacy and tolerability of crenolanib
in two cohorts of AML patients with FLT3 activation mutations (patients whose leukemia has
recurred after prior chemotherapy not including a FLT3 TKI and patients whose leukemia has
progressed after prior therapy with a FLT3 TKI).